Compare Innodata Inc (INOD) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Nuwellis Inc — how do they compare? Innodata Inc trades at $61.84 (market cap $2.10B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Innodata Inc is far larger — about 954.5× Nuwellis Inc's market cap, and Innodata Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Nuwellis Inc for 26 Days on average.
| INOD | NUWE | |
|---|---|---|
Market Cap | $2.10B | $2.20M |
Volume | 989,493 | 121,544 |
Sector | Technology | Health |
52-Week High | $121.50 | $146.65 |
52-Week Low | $34.45 | $0.68 |
Typical Hold Time | 19 Days | 26 Days |
Enterprise Value | $1.86B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $61.54, down 2.96% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consecutive earnings beats, with Q1 2026 EPS of $0.42 significantly exceeding the $0.13 estimate, and demonstrated robust revenue growth from $252M in 2025 to $317M projected for 2026. Analyst sentiment remains positive with a 67% buy rating, though the stock faces valuation concerns with a P/E of 47.4.
The outlook for INOD is mixed: strong AI-driven revenue growth and expanding margins support upside potential, but high valuation multiples and bearish technical signals present near-term risks. Investor focus should remain on execution of new initiatives like the motion-capture AI lab and customer diversification efforts to justify premium pricing.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
